Author: Antonio Gonçalves; Julie Bertrand; Ruian Ke; Emmanuelle Comets; Xavier de Lamballerie; Denis Malvy; Andrés Pizzorno; Olivier Terrier; Manuel Rosa Calatrava; France Mentré; Patrick Smith; Alan S Perelson; Jérémie Guedj
Title: Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load Document date: 2020_4_7
ID: n6l2804j_27
Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.04.20047886 doi: medRxiv preprint appear to have low mutation rates due to RNA proofreading capability. Drug combination 199 therapy and more aggressive dosing, including consideration of loading doses to rapidly 200 achieve therapeutic exposures, may be beneficial to maximize efficacy of these repurposed 201 antiviral agents. However, th.....
Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.04.20047886 doi: medRxiv preprint appear to have low mutation rates due to RNA proofreading capability. Drug combination 199 therapy and more aggressive dosing, including consideration of loading doses to rapidly 200 achieve therapeutic exposures, may be beneficial to maximize efficacy of these repurposed 201 antiviral agents. However, they may be relevant in pre-or post-exposure prophylaxis 202 administration to reduce viral replication and hence the risk of disease progression. 203
Search related documents:
Co phrase search for related documents- antiviral agent and disease progression: 1, 2, 3, 4, 5
- antiviral agent and disease progression risk: 1, 2
- antiviral agent and dose loading: 1, 2
- antiviral agent and drug combination: 1, 2, 3, 4, 5, 6
- antiviral agent and mutation rate: 1
- antiviral agent and viral replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49
- disease progression and dose loading: 1, 2, 3, 4, 5, 6
- disease progression and drug combination: 1, 2, 3, 4, 5, 6
- disease progression and mutation rate: 1, 2
- disease progression and viral replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- disease progression risk and dose loading: 1
- disease progression risk and viral replication: 1
- dose loading and viral replication: 1, 2, 3
- drug combination and mutation rate: 1
- drug combination and viral replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- mutation rate and proofreading capability: 1
- mutation rate and rna proofreading capability: 1
- mutation rate and viral replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- proofreading capability and rna proofreading capability: 1
Co phrase search for related documents, hyperlinks ordered by date